BioLineRx (NASDAQ:BLRX) Shares Cross Above 200-Day Moving Average – Here’s What Happened

Posted by ABMN Staff on Jul 17th, 2026

BioLineRx Ltd. (NASDAQ:BLRX – Get Free Report) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.87 and traded as high as $3.07. BioLineRx shares last traded at $2.98, with a volume of 7,371 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioLineRx in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Get Our Latest Stock Analysis on BLRX

BioLineRx Trading Up 2.4%

The firm has a market cap of $13.02 million, a PE ratio of -1.55 and a beta of 1.55. The company has a current ratio of 1.58, a quick ratio of 1.43 and a debt-to-equity ratio of 0.16. The business has a fifty day moving average price of $3.16 and a 200 day moving average price of $2.87.

BioLineRx (NASDAQ:BLRX – Get Free Report) last issued its earnings results on Wednesday, May 27th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.68. The business had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.34 million. BioLineRx had a negative return on equity of 37.73% and a negative net margin of 563.70%.

BioLineRx Company Profile

(Get Free Report)

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.